CytomX Therapeutics (CTMX) Construction in Progress (2017 - 2023)

CytomX Therapeutics has reported Construction in Progress for 7 years, with the latest figure at $368000.0 in Q4 2023.

• For the quarter ending Q4 2023, Construction in Progress fell 47.8% year-over-year to $368000.0; the trailing twelve-month figure through Dec 2023 stood at $368000.0 (down 47.8% YoY), and the FY2023 full-year result was $368000.0, down 47.8% from the prior year.
• Construction in Progress for Q4 2023 stood at $368000.0, down from $705000.0 in the prior quarter.
• The five-year high for Construction in Progress was $705000.0 in Q4 2022, with the low at $236000.0 in Q4 2019.
• Historically, Construction in Progress has averaged $373800.0 across 5 years, with a median of $308000.0 in 2021.
• Annual changes were most pronounced in 2019 — Construction in Progress plunged 69.94% — and 2022, when it surged 128.9%.
• CytomX Therapeutics' Construction in Progress stood at $236000.0 in 2019, then increased by 6.78% to $252000.0 in 2020, then climbed by 22.22% to $308000.0 in 2021, then surged by 128.9% to $705000.0 in 2022, then tumbled by 47.8% to $368000.0 in 2023.
• The last three Construction in Progress figures came in at $368000.0 (Q4 2023), $705000.0 (Q4 2022), and $308000.0 (Q4 2021), per Business Quant data.